Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders

Schizophrenia Research

Volumn 165, Issue 1, 2015, Pages 103-107

  Mothi, Suraj Sarvode ^a,b   Tandon, Neeraj ^b,c   Padmanabhan, Jaya ^b   Mathew, Ian T ^b   Clementz, Brett ^f   Tamminga, Carol ^g   Pearlson, Godfrey ^d,e   Sweeney, John ^f   Keshavan, Matcheri S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d INSTITUTE OF LIVING   (United States)

^e YALE UNIVERSITY   (United States)

^f UNIVERSITY OF GEORGIA   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diabetes; Hypertension; Psychotic disorder; Relatives

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FIRST DEGREE RELATIVE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PREVALENCE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL STATUS; CARDIOVASCULAR DISEASES; CLASSIFICATION; COMPLICATION; FAMILY; GENETICS; METABOLIC DISEASES; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; FAMILY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC DISEASES; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 84929510158     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.03.034     Document Type: Article

References (52)

1. Andreassen O.A., Djurovic S., Thompson W.K., Schork A.J., Kendler K.S., O'Donovan M.C., Rujescu D., Werge T., van de Bunt M., Morris A.P., McCarthy M.I., International Consortium for Blood Pressure GWAS, Diabetes Genetics Replication, Meta-analysis Consortium, Psychiatric Genomics Consortium Schizophrenia Working Group, Roddey J.C., McEvoy L.K., Desikan R.S., Dale A.M. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am. J. Hum. Genet. 2013, 92:197-209. 10.1016/j.ajhg.2013.01.001.
2. Bergmann M.M., Byers T., Freedman D.S., Mokdad A. Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. Am. J. Epidemiol. 1998, 147:969-977.
3. Birkenaes A.B., Opjordsmoen S., Brunborg C., Engh J.A., Jonsdottir H., Ringen P.A., Simonsen C., Vaskinn A., Birkeland K.I., Friis S., Sundet K., Andreassen O.A. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J. Clin. Psychiatry 2007, 68:917-923.
4. Brown S., Kim M., Mitchell C., Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br. J. Psychiatry 2010, 196:116-121. 10.1192/bjp.bp.109.067512.
5. Caqueo-Urízar A., Gutiérrez-Maldonado J., Miranda-Castillo C. Quality of life in caregivers of patients with schizophrenia: a literature review. Health Qual Life Outcomes 2009, 7:84. 10.1186/1477-7525-7-84.
6. Caqueo-Urízar A., Gutiérrez-Maldonado J., Ferrer-García M., Peñaloza-Salazar C., Richards-Araya D., Cuadra-Peralta A. Attitudes and burden in relatives of patients with schizophrenia in a middle income country. BMC Fam. Pract. 2011, 12:101. 10.1186/1471-2296-12-101.
7. Chaturvedi N., Jarrett J., Shipley M.J., Fuller J.H. Socioeconomic gradient in morbidity and mortality in people with diabetes: cohort study findings from the Whitehall Study and the WHO Multinational Study of Vascular Disease in Diabetes. BMJ 1998, 316:100-105. 10.1136/bmj.316.7125.100.
8. Christakis N.A., Fowler J.H. The spread of obesity in a large social network over 32years. N. Engl. J. Med. 2007, 357:370-379. 10.1056/NEJMsa066082.
9. Chwastiak L.A., Rosenheck R.A., McEvoy J.P., Keefe R.S., Swartz M.S., Lieberman J.A. Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatr. Serv. 2006, 57:1102-1109. 10.1176/appi.ps.57.8.1102.
10. Correll C.U., Robinson D.G., Schooler N.R., Brunette M.F., Mueser K.T., Rosenheck R.A., Marcy P., Addington J., Estroff S.E., Robinson J., Penn D.L., Azrin S., Goldstein A., Severe J., Heinssen R., Kane J.M. Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders: Baseline Results From the RAISE-ETP Study. JAMA Psychiatry 2014, 71:1350-1363. 10.1001/jamapsychiatry.2014.1314.
11. Fernandez-Egea E., Bernardo M., Parellada E., Justicia A., Garcia-Rizo C., Esmatjes E., Conget I., Kirkpatrick B. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr. Res. 2008, 103:110-113. 10.1016/j.schres.2008.04.017.
12. Fernandez-Egea E., Miller B., Bernardo M., Donner T., Kirkpatrick B. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr. Res. 2008, 98:302-306. 10.1016/j.schres.2007.10.002.
13. First M.B., Spitzer R.L., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV® Axis I Disorders (SCID-I), Clinician Version, 2012, Administration Booklet.
14. Fleischhacker W.W., Cetkovich-Bakmas M., De Hert M., HENNEKENS C.H., Lambert M., Leucht S., Maj M., McIntyre R.S., Naber D., Newcomer J.W., Olfson M., Osby U., Sartorius N., Lieberman J.A. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. Presented at The Journal of Clinical Psychiatry 2008, 514-519.
15. Gough S.C.L., O'Donovan M.C. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. J. Psychopharmacol. 2005, 19:47-55. 10.1177/0269881105058380.
16. Hosmer D.W., Lemeshow S., Sturdivant R.X. Applied logistic regression 2013.
17. Jeste D.V., Gladsjo J.A., Lindamer L.A., Lacro J.P. Medical Comorbidity in Schizophrenia. Schizophr. Bull. 1996, 22:413-430. 10.1093/schbul/22.3.413.
18. Kanjilal S., Gregg E.W., Cheng Y.J., Zhang P., Nelson D.E., Mensah G., Beckles G.L.A. Socioeconomic Status and Trends in Disparities in 4 Major Risk Factors for Cardiovascular Disease Among US Adults, 1971-2002. Arch. Intern. Med. 2006, 166:2348-2355. 10.1001/archinte.166.21.2348.
19. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
20. Kim B., Kim S., McIntyre R.S., Park H.J., Kim S.Y., Joo Y.H. Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment. Psychiatry Invest. 2009, 6:78-84. 10.4306/pi.2009.6.2.78.
21. Kirkpatrick B. Schizophrenia as A Systemic Disease. Schizophr. Bull. 2009, 35:sbn183-sbn382. 10.1093/schbul/sbn183.
22. Laursen T.M. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr. Res. 2011, 131:101-104. 10.1016/j.schres.2011.06.008.
23. Laursen T.M., Munk-Olsen T., Agerbo E., Gasse C., Mortensen P.B. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch. Gen. Psychiatry 2009, 66:713-720. 10.1001/archgenpsychiatry.2009.61.
24. Laursen T.M., Mortensen P.B., MacCabe J.H., Cohen D., Gasse C. Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study. Psychol. Med. 2014, 44:1625-1637. 10.1017/S003329171300216X.
25. Laursen T.M., Nordentoft M., Mortensen P.B. Excess early mortality in schizophrenia. Annu. Rev. Clin. Psychol. 2014, 10:425-448. 10.1146/annurev-clinpsy-032813-153657.
26. Leboyer M., Soreca I., Scott J., Frye M., Henry C., Tamouza R., Kupfer D.J. Can bipolar disorder be viewed as a multi-system inflammatory disease?. J. Affect. Disord. 2012, 141:1-10. 10.1016/j.jad.2011.12.049.
27. Linet M.S., Harlow S.D., McLaughlin J.K., McCaffrey L.D. A comparison of interview data and medical records for previous medical conditions and surgery. J. Clin. Epidemiol. 1989, 42:1207-1213.
28. Liu Y., Li Z., Zhang M., Deng Y., Yi Z., Shi T. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med. Genet. 2013, 6(Suppl. 1):S17. 10.1186/1755-8794-6-S1-S17.
29. Maina G., Salvi V., Vitalucci A., D'Ambrosio V., Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J. Affect. Disord. 2008, 110:149-155. 10.1016/j.jad.2007.12.233.
30. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80:19-32. 10.1016/j.schres.2005.07.014.
31. Miller B.J., Paschall C.B., Svendsen D.P. Mortality and Medical Comorbidity Among Patients With Serious Mental Illness. Focus 2008, 6:239-245. 10.1176/appi.ps.53.7.861.
32. Möller-Leimkühler A.M., Wiesheu A. Caregiver burden in chronic mental illness: the role of patient and caregiver characteristics. Eur. Arch. Psychiatry Clin. Neurosci. 2012, 262:157-166. 10.1007/s00406-011-0215-5.
33. Moons K.G.M., Donders R.A.R.T., Stijnen T., Harrell F.E. Using the outcome for imputation of missing predictor values was preferred. J. Clin. Epidemiol. 2006, 59:1092-1101. 10.1016/j.jclinepi.2006.01.009.
34. Mukherjee S., Schnur D.B., Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989, 1:495.
35. Nordentoft M., Wahlbeck K., Hällgren J., Westman J., Osby U., Alinaghizadeh H., Gissler M., Laursen T.M. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One 2013, 8:e55176. 10.1371/journal.pone.0055176.
36. Osborn D.P.J., Wright C.A., Levy G., King M.B., Deo R., Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry 2008, 8:84. 10.1186/1471-244X-8-84.
37. Perlick D.A., Miklowitz D.J., Lopez N., Chou J., Kalvin C., Adzhiashvili V., Aronson A. Family-focused treatment for caregivers of patients with bipolar disorder. Bipolar Disord. 2010, 12:627-637. 10.1111/j.1399-5618.2010.00852.x.
38. Pfohl B., Blum N., Zimmerman M. Structured interview for DSM-IV personality 1997.
39. Regenold W.T., Thapar R.K., Marano C., Gavirneni S., Kondapavuluru P.V. Increased prevalence of type 2 diabetes mellitus among psychiatric in patients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J. Affect. Disord. 2002, 70:19-26.
40. Reinares M., Vieta E., Colom F., Martínez-Arán A., Torrent C., Comes M., Goikolea J.M., Benabarre A., Daban C., Sánchez-Moreno J. What really matters to bipolar patients' caregivers: sources of family burden. J. Affect. Disord. 2006, 94:157-163. 10.1016/j.jad.2006.04.022.
41. Rudisch B., Nemeroff C.B. Epidemiology of comorbid coronary artery disease and depression. Biol. Psychiatry 2003, 54:227-240.
42. Ryan M.C.M., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160:284-289.
43. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry 2007, 64:1123-1131. 10.1001/archpsyc.64.10.1123.
44. Saydah S.H., Imperatore G., Beckles G.L. Socioeconomic status and mortality: contribution of health care access and psychological distress among U.S. adults with diagnosed diabetes. Diabetes Care 2013, 36:49-55. 10.2337/dc11-1864.
45. Schulz R., Newsom J., Mittelmark M., Burton L., Hirsch C., Jackson S. Health effects of caregiving: the caregiver health effects study: an ancillary study of the Cardiovascular Health Study. Ann. Behav. Med. 1997, 19:110-116.
46. Selim A.J., Fincke G., Ren X.S., Lee A., Rogers W.H., Miller D.R., Skinner K.M., Linzer M., Kazis L.E. Comorbidity assessments based on patient report: results from the Veterans Health Study. J. Ambul. Care Manage. 2004, 27:281-295.
47. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet. Med. 2007, 24:481-485. 10.1111/j.1464-5491.2007.02092.x.
48. Tamminga C.A., Ivleva E.I., Keshavan M.S., Pearlson G.D., Clementz B.A., Witte B., Morris D.W., Bishop J., Thaker G.K., Sweeney J.A. Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am. J. Psychiatry 2013, 170:1263-1274. 10.1176/appi.ajp.2013.12101339.
49. van der Heijden G.J., M.G., T, Donders A.R., Stijnen T., Moons K.G.M. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. J. Clin. Epidemiol. 2006, 59:1102-1109. 10.1016/j.jclinepi.2006.01.015.
50. van Welie H., Derks E.M., Verweij K.H., de Valk H.W., Kahn R.S., Cahn W. The prevalence of diabetes mellitus is increased in relatives of patients with a non-affective psychotic disorder. Schizophr. Res. 2013, 143:354-357. 10.1016/j.schres.2012.11.011.
51. Vancampfort D., Wampers M., Mitchell A.J., Correll C.U., Herdt A., Probst M., Hert M. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013, 12:240-250. 10.1002/wps.20069.
52. Woodhead C., Ashworth M., Schofield P., Henderson M. Patterns of physical co-/multi-morbidity among patients with serious mental illness: a London borough-based cross-sectional study. BMC Fam. Pract. 2014, 15:117. 10.1186/1471-2296-15-117.